Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma
NCT04025931Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2020
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and toripalimab in soft tissue sarcoma (STS), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate up to 24 months. Started Jan 2020; status: completed.
02
Drugs
tucidinostattoripalimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04025931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04025931.